Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 6/20 | 0.47 |
| ▸ | HTR6 | P50406 | 6/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16205347 | 0.95 | MAP3K14 (0.43) | MAP3K14HTR6CDK6CCND1 | |
| SCHEMBL16205520 | 0.94 | MAP3K14 (0.41) | MAP3K14CDK6CCND1 | |
| SCHEMBL19627454 | 0.93 | MAP3K14 (0.43) | MAP3K14HTR6 | |
| SCHEMBL16205344 | 0.93 | MAP3K14 (0.41) | MAP3K14 | |
| SCHEMBL16205576 | 0.92 | MAP3K14 (0.41) | MAP3K14CDK6 | |
| SCHEMBL19627460 | 0.91 | MAP3K14 (0.42) | MAP3K14 | |
| SCHEMBL16205625 | 0.89 | MAP3K14 (0.38) | MAP3K14CDK6 | |
| SCHEMBL19627461 | 0.89 | MAP3K14 (0.40) | MAP3K14 | |
| SCHEMBL16205391 | 0.88 | MAP3K14 (0.37) | MAP3K14HTR6 | |
| SCHEMBL16205387 | 0.88 | MAP3K14 (0.39) | MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643964-B2 | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| US-9643964-B2 | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| US-20160075699-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-03-17 | — | — | US | disclosed |
| WO-2014174021-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075699-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | NFKBIA, IKBKG, MAP3K14 | MAP3K14 3/4885HTR6 4602/4885MTOR 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.